Morgan Stanley analyst Terrance Flynn reiterated an Overweight rating and $185.00 price target on Abbvie (NYSE: ABBV) and named the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE